Terrance D. Barrett - Concepedia

Author

Terrance D. Barrett

Also Known As

Barrett, T.D., Barrett, Terrance Donald, T D Barrett, T. D. Barrett, T.D. Barrett, TERRANCE D. BARRETT, Terrance Barrett, Terrance D Barrett, Terrance D. Barrett

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Johnson & Johnson (United States)University of Michigan University of British Columbia University of Groningen University Medical Center Groningen

About

Terrance D. Barrett is an author at Johnson & Johnson (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	1.1K
2	Public Health	4	4	93
3	Natural Sciences	3	3	134
4	Health Sciences	1	1	117
5	Anesthesia	1	1	36

Terrance D. Barrett

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, The Lancet Diabetes & Endocrinology ObesityMetabolic SyndromeDiabetes ManagementUrologyHealth Policy	2018	632
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus Karin Rådholm, Gemma A. Figtree, Vlado Perkovic, Circulation	2018	469
Effects of Selective Cyclooxygenase-2 Inhibition on Vascular Responses and Thrombosis in Canine Coronary Arteries James K. Hennan, Jinbao Huang, Terrance D. Barrett, Circulation	2001	162
RETRACTED: Obestatin reduces food intake and suppresses body weight gain in rodents Guy Lagaud, Andy Young, Auzon Acena, Biochemical and Biophysical Research Communications ObesityMetabolic SyndromeNutritionEnergy HomeostasisAppetite Control	2007	117
C-Reactive-Protein-Associated Increase in Myocardial Infarct Size After Ischemia/Reperfusion Terrance D. Barrett, James K. Hennan, Rory M. Marks, Journal of Pharmacology and Experimental Therapeutics	2002	92
Pharmacological Characterization of 1-(5-Chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic Acid (JNJ-42041935), a Potent and Selective Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Terrance D. Barrett, Heather L. Palomino, Theresa I. Brondstetter, Molecular Pharmacology	2011	72
Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues Mark D. Rosen, Hariharan Venkatesan, Hillary M. Peltier, ACS Medicinal Chemistry Letters Erythropoietin SecretionPharmacotherapyRedox BiologyOxidative StressSystems Pharmacology	2010	62
Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation‐induced anaemia in rats Terrance D. Barrett, Heather L. Palomino, Theresa I. Brondstetter, British Journal of Pharmacology	2015	43
Risk of Ventricular Proarrhythmia with Selective Opening of the Myocardial Sarcolemmal versus Mitochondrial ATP-Gated Potassium Channel Peter Fischbach, Andrew A. White, Terrance D. Barrett, Journal of Pharmacology and Experimental Therapeutics	2004	41
Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2α (HRI) kinase Mark D. Rosen, Craig R. Woods, Steven D. Goldberg, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyNatural SciencesMolecular BiologyHeme SignalingSmall-molecule Inhibitors	2009	40

Page 1